ProteoSil HILIC Analytical Column 1.9um, 2.1x100mm (U)HPLC Column

The ProteoSil HILIC HPLC column 100x2.1mm, 1.9µm, features an amide modification on high-purity silica. This makes the ProteoSil HILIC suitable for use in hydrophilic interaction chromatography. This phase is particularly suitable when highly polar or hydrophilic analytes are only weakly retained in reverse-phase chromatography. Using the HILIC mechanism, peptides, glycans, oligonucleotides, and other hydrophilic biomolecules can be separated. Compared to C18 phases, the amide surface provides a significantly different selectivity, which can be advantageous for polar peptide fragments, sugar structures, and water-soluble bioanalytes in LC/MS methods.

Features and Benefits

• Bio-LC column series for proteins, peptides, oligonucleotides, nucleic acids, and biopharmaceutical applications
• High-purity silica with controlled pore sizes of 100 Å, 200 Å, and 300 Å
• Choice between reverse-phase, HILIC, and size-exclusion chromatography
• Stainless steel, PEEK, and bio-inert hardware for various requirements
• Low lot-to-lot variability and consistent quality, even for LC/MS methods

Additional Information

The ProteoSil series is designed for bioseparations in which pore size, modification, and hardware must be specifically tailored to sensitive biomolecules. It is based on a high-purity silica matrix with pore sizes of 100 Å, 200 Å, or 300 Å. Smaller pores are particularly suitable for low-molecular-weight peptides, while 200 Å materials are used for medium-sized peptides and oligonucleotides. For larger proteins, hydrophobic peptides, and antibodies, 300 Å materials are available. In addition, ProteoSil HILIC and ProteoSil SEC round out the series for hydrophilic analytes and size-based separations. Using appropriate ProteoSil pre-column cartridges or guard columns, the analytical column can be protected from particles, strongly adsorbing sample components, and matrix carryover.

Legal Information

ProteoSil is a registered trademark of the manufacturer GL Sciences Inc., Tokyo, Japan.